S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:GNVC - GenVec Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$7.19
0.00 (0.00 %)
(As of 06/26/2017)
Add
Today's Range
$7.19
Now: $7.19
$7.19
50-Day Range N/A
52-Week Range
$2.70
Now: $7.19
$10.44
VolumeN/A
Average Volume259,136 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:GNVC
CUSIPN/A
Phone+1-240-6320740

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive GNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for GNVC and its competitors with MarketBeat's FREE daily newsletter.


GenVec (NASDAQ:GNVC) Frequently Asked Questions

What is GenVec's stock symbol?

GenVec trades on the NASDAQ under the ticker symbol "GNVC."

When did GenVec's stock split? How did GenVec's stock split work?

GenVec's stock reverse split on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.

How were GenVec's earnings last quarter?

GenVec Inc (NASDAQ:GNVC) issued its earnings results on Friday, November, 4th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.07 million. View GenVec's Earnings History.

Has GenVec been receiving favorable news coverage?

Media headlines about GNVC stock have been trending positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GenVec earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for GenVec.

What other stocks do shareholders of GenVec own?

Who are GenVec's key executives?

GenVec's management team includes the folowing people:
  • Wayne T. Hockmeyer Ph.D., Independence Chairman of the Board
  • Douglas J. Swirsky, President, Chief Executive Officer, Corporate Secretary, Director
  • William N. Kelley M.D., Independent Director
  • Stefan D. Loren Ph.D., Independent Director
  • Quinterol J. Mallette M.D., Independent Director
  • Michael S. Richman, Independent Director
  • Marc R. Schneebaum, Independent Director

What is GenVec's stock price today?

One share of GNVC stock can currently be purchased for approximately $7.19.

What is GenVec's official website?

The official website for GenVec is http://www.genvec.com/.

How can I contact GenVec?

GenVec's mailing address is 910 Clopper Rd Ste 220n, GAITHERSBURG, MD 20878-1353, United States. The biopharmaceutical company can be reached via phone at +1-240-6320740.


MarketBeat Community Rating for GenVec (NASDAQ GNVC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about GenVec and other stocks. Vote "Outperform" if you believe GNVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: How is inflation measured?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel